BESORFIB Trademark

Trademark Overview

On Wednesday, April 15, 2020, a trademark application was filed for BESORFIB with the United States Patent and Trademark Office. The USPTO has given the BESORFIB trademark a serial number of 88873862. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 30, 2023. This trademark is owned by Pfizer Inc.. The BESORFIB trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
besorfib

General Information

Serial Number88873862
Word MarkBESORFIB
Filing DateWednesday, April 15, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 30, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 4, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 27, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, October 30, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 30, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, March 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 28, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 28, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, February 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 13, 2023SOU EXTENSION 5 GRANTED
Thursday, January 26, 2023SOU EXTENSION 5 FILED
Monday, February 13, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, January 26, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 10, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 8, 2022SOU EXTENSION 4 GRANTED
Monday, August 8, 2022SOU EXTENSION 4 FILED
Monday, August 8, 2022SOU TEAS EXTENSION RECEIVED
Saturday, January 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 27, 2022SOU EXTENSION 3 GRANTED
Thursday, January 27, 2022SOU EXTENSION 3 FILED
Thursday, January 27, 2022SOU TEAS EXTENSION RECEIVED
Saturday, July 31, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 29, 2021SOU EXTENSION 2 GRANTED
Thursday, July 29, 2021SOU EXTENSION 2 FILED
Thursday, July 29, 2021SOU TEAS EXTENSION RECEIVED
Friday, January 29, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 27, 2021SOU EXTENSION 1 GRANTED
Wednesday, January 27, 2021SOU EXTENSION 1 FILED
Wednesday, January 27, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, September 29, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 4, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 4, 2020PUBLISHED FOR OPPOSITION
Wednesday, July 15, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 24, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 23, 2020ASSIGNED TO EXAMINER
Monday, April 27, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, April 18, 2020NEW APPLICATION ENTERED

Related Keywords

besorfib preparations disorders pharmaceutical treatment hypertension pain stroke cancer growth bone